Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.

Phase 2

Completed

• Conditions: Haemophilia A

• Registration Number: NCT00245297
• Lead Sponsor: Recoly N.V.

Brief Summary

Primary efficacy endpoint: To study whether there is a difference in the length of the bleeding free periods between infusion of FVIII that is reconstituted with 22.1, 12.6, or 4.2 mg of pegylated liposomes per kg bwt compared with standard formulation.

Safety endpoint: To study the safety and tolerability of Kogenate FS reconstituted with Pegylated liposomes

Detailed Description

Each subject will receive treatment for three bleeding episodes ("wash-in", on demand injections) followed by a minimum 4 day wash-out. Following this each subject will be randomized to a specific treatment order. Each order consists of four identical blocks. In each block the following three injections will be given: 1 One prophylactic treatment (randomized solution for dissolution) 2 and 3. Two standard on-demand treatments for a spontaneous bleeding episode (standard Kogenate FS). Each block will be followed by a four day wash-out. In total each subject should receive 3+4x3=15 injections. It is estimated that each subject will be in the study for about 4 months. A treatment for a spontaneous bleeding episode may require more than one infusion.

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2005-10-26
• Study First Submitted QC: 2005-10-26
• Study First Posted: 2005-10-27
• Study Completion: 2006-04
• Status Verified: 2007-10
• Last Update Submitted: 2007-10-15
• Last Update Posted: 2007-10-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 16

Inclusion Criteria

• Between 18 and 60 years of age
• Severe haemophilia A (≤ 1% of baseline Factor VIII activity)
• At least 250 treatment cumulative exposure-days (CEDs) to previous products
• At least 25 cumulative exposure-days (CEDs) to previous products during one year prior to study start
• If HIV positive, CD4 lymphocytes ≥ 400/µl
• Subjects on demand treatment, and with a minimum bleeding/treatment pattern of a four episodes per month, evenly distributed within each month, during the three month preceding study start
• Subjects who have given their written informed consent.

Exclusion Criteria

• Inhibitors or history of inhibitors
• History of adverse reactions related to Factor VIII
• Platelet count <90,000 /µl
• Subjects on prophylaxis treatment
• Subjects with concomitant debilitating disease (e.g. cancer, non-controlled diabetes, heart insufficiency, renal failure)
• Subjects with known sensitivity to blood products
• Subjects who have participated in another Ethical Committee approved Clinical Trial (including medical device studies) within the past 30 days
• Subjects with a weight over 86 kg or below 50 kg
• Subjects who do not understand or are not willing to comply with the requirement of the study protocol
• Subjects who cannot differentiate a bleeding episode from other causes of joint pain

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
The primary efficacy parameter is the number of bleeding free days (without a bleeding/treatment) between a randomized prophylactic infusion and following on demand injection.	Bleeding free time following four single doses will be studies

Secondary Outcome Measures

Name	Time	Method
In vivo recovery (IVR).	IVR will be performed at the first and last dose.

Trial Locations

Locations (3)

Republic Haemophilia Center.; 🇷🇺 St. Petersburg, Russian Federation

The Russian Academy of Medical Sciences, Haemophilia Center; 🇷🇺 Moscow, Russian Federation

Center for Hematological Research, Department of Reconstructive Orthopedic Surgery; 🇷🇺 Moscow, Russian Federation